2026-05-10T14:28:24Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/96182024-09-27T08:03:20Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Wculek, Stefanie K author Cueto, Francisco J. author Mujal, Adriana M author Melero, Ignacio author Krummel, Matthew F author Sancho, David author 2020-01 Dendritic cells (DCs) are a diverse group of specialized antigen-presenting cells with key roles in the initiation and regulation of innate and adaptive immune responses. As such, there is currently much interest in modulating DC function to improve cancer immunotherapy. Many strategies have been developed to target DCs in cancer, such as the administration of antigens with immunomodulators that mobilize and activate endogenous DCs, as well as the generation of DC-based vaccines. A better understanding of the diversity and functions of DC subsets and of how these are shaped by the tumour microenvironment could lead to improved therapies for cancer. Here we will outline how different DC subsets influence immunity and tolerance in cancer settings and discuss the implications for both established cancer treatments and novel immunotherapy strategies. Nat Rev Immunol. 2020; 20(1):7-24 10.1038/s41577-019-0210-z 1474-1741 1474-1733 Nature reviews. Immunology 31467405 http://hdl.handle.net/20.500.12105/9618 Dendritic cells in cancer immunology and immunotherapy